Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid
Akira Honda, Tadashi Ikegami, Makoto Nakamuta, Teruo Miyazaki, Junichi Iwamoto, Takeshi Hirayama, Yoshifumi Saito, Hajime Takikawa, Michio Imawari, Yasushi Matsuzaki – 22 August 2012 – Bezafibrate is a widely used hypolipidemic agent and is known as a ligand of the peroxisome proliferator‐activated receptors (PPARs). Recently this agent has come to be recognized as a potential anticholestatic medicine for the treatment of primary biliary cirrhosis (PBC) that does not respond sufficiently to ursodeoxycholic acid (UDCA) monotherapy.